Controlled delivery of pilocarpine. 2. In-vivo evaluation of Gelfoam® device

International Journal of Pharmaceutics

Volumn 170, Issue 2, 1998, Pages 209-214

  Simamora, P ^a,d   Nadkarni, S R ^b   Lee, Y C ^c   Yalkowsky, S H ^c  

^a MOVA Pharmaceutical Corporation   (Puerto Rico)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Controlled delivery; Gelfoam; Ocular device; Pilocarpine

Indexed keywords

EYE DROPS; GELFOAM; PILOCARPINE; PILOPAR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSAGE FORM; DRUG FORMULATION; FEMALE; GEL; INTRAOCULAR DRUG ADMINISTRATION; MALE; MIOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032529019     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00141-0     Document Type: Article

References (13)

1. Armaly, M.F., Rao, K.R., 1973. The effect of pilocarpine Ocusert with different release rates on ocular pressure. Invest. Ophthalmol. 12, 491-496.
2. Benita, S., Plenecassagne, J.D., Gave, G., Drovin, D., Le Hao Dong, D., Sincholle, D., 1984. Pilocarpine hydrochloride liposomes: characterization in vitro and preliminary evaluation in vivo in rabbit eye. J. Microencaps. 1, 203-216.
3. Cohen, S., Lobel, E., Trevgoda, A., Peled, Y., 1997. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J. Control. Rel. 44, 201-208.
4. Deshpande, S.G., Shirolkal, S., 1989. Sustained release ophthalmic formulations of pilocarpine. J. Pharm. Pharmacol. 41, 197-200.
5. Diepold, R., Kreuter, J., Himber, J., Gurny, R., Lee, V.H.L., Robinson, J.R., Saettone, M.F., Schnaudigel, O.E., 1989. Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparticles). Graefes Arch. Clin. Exp. Ophthalmol. 227, 188-193.
6. Grass, G.M., Cobby, J., Makoid, M.C., 1984. Ocular delivery of pilocarpine from erodible matrices. J. Pharm. Sci. 73, 618-621.
7. Gurtler, F., Gurny, R., 1995. Patent literature review of ophthalmic inserts. Drug Dev. Ind. Pharm. 21, 1-18.
8. Le Bourlais, C.A., Treupel-Acar, L., Rhodes, C.T., Sado, P.A., Leverge, R., 1995. New ophthalmic drug delivery systems. Drug Dev. Ind. Pharm. 21, 19-59.
9. Lee, V.H.L., Robinson, J.R., 1986. Review: topical ocular drug delivery: recent developments and future chalanges. J. Ocul. Pharmacol. 2, 67-108.
10. Lee, Y.-C., Simamora, P., Yalkowsky, S.H., 1997. Systemic delivery of insulin via an enhancer-free ocular device. J. Pharm. Sci. 86, 1361-1364.
11. Maichuk, Y.F., 1975. Ophthalmic drug insert. Invest. Ophthalmol. 14, 87-90.
12. March, W.F., Stewart, R.M., Mandell, A.I., Bruce, L.A., 1982. Duration of effect of pilocarpine gel. Arch. Ophthalmol. 100, 1270-1271.
13. Meisner, D., Pringle, J., Mezei, M., 1989. Liposomal ophthalmic drug delivery. III. Pharmacodynamic and biodisposition studies of atropine. Int. J. Pharm. 55, 105-113.